Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 192
- 试验地点
- 2
- 主要终点
- The primary outcome is a composite of the following: 1. All-cause in-hospital death AND/OR 2. Any in-hospital ventricular arrhythmia requiring treatment after study drug initiation.
研究概览
简要总结
The objective of this study is to determine if there is a meaningful benefit to using the sedative medication dexmedetomidine in the acute treatment of patients with recurrent ventricular arrhythmias, known as electrical storm. This will be a multi-centre, double-blinded, placebo-controlled, randomized trial. Patients with electrical storm will be randomized to receive 48 to 72 hours of dexmedetomidine or placebo as part of their initial treatment in an intensive care unit.
详细描述
Electrical storm (ES), defined as three or more sustained or treated ventricular arrhythmias in a 24-hour period, is a life-threatening condition that is associated with significant short- and long-term mortality. Autonomic dysfunction from increased sympathetic tone and the catecholamine surge from defibrillator shocks can precipitate recurrent ventricular arrhythmias and exacerbate ES. Although the mainstay of treatment are anti-arrhythmic drugs, sedative agents and procedures are commonly used to decrease sympathetic tone. These therapies have been studied in refractory ES but the benefit of early sedation remains unclear.
Alpha-2 agonism with dexmedetomidine can provide conscious sedation without the need for mechanical ventilation. Dexmedetomidine has been found to reduce ventricular arrhythmia events in non-ES patients in the intensive care unit and in the peri-operative period. Its antiarrhythmic properties are thought to be due to catecholamine suppression, prolonging electrical refractory periods, and increasing vagal tone. Its rapid onset and favorable safety profile render alpha-2 agonism with dexmedetomidine a potentially valuable therapy for patients with ES.
This study is a multi-centre, double-blinded, placebo-controlled, randomized trial that will evaluate the effectiveness of dexmedetomidine in the acute treatment of ES. Consecutive patients admitted to an intensive care unit will be randomized to receive dexmedetomidine or placebo at the time of presentation. The study drug will be titrated to a maintenance dose and continued for 48 hours before being weaned.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
盲法说明
Double-blind
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •- All patients admitted to an intensive care unit with electrical storm over the age of 18 years will be approached for enrollment.
排除标准
- •Refractory shock lasting for more than 30 minutes unrelated to ventricular arrhythmias (VAs), defined as requiring two or more vasopressors
- •SCAI class D or E cardiogenic shock
- •Cardiac arrest(s) with a no-flow and low-flow total time of greater than 10 minutes prior to recruitment.
- •ST-segment elevation myocardial infarction (STEMI)-induced VA with signs of active ischemia.
- •Bradycardia with heart rate less than 40 beats per minute, bradycardia-induced ventricular tachyarrhythmia, second degree Mobitz type 2 or greater atrioventricular block in the absence of a pacemaker.
- •Pregnancy
- •Known dexmedetomidine allergy or intolerance
- •Inability to obtain consent from patient or substitute decision maker.
- •Patients who have received dexmedetomidine or clonidine during the 24 hours prior to randomization
研究组 & 干预措施
Dexmedetomidine
Participants randomized to receive dexmedetomidine will be started at a dose of 0.3 mcg/kg/hr and titrated to a target dose of 1.0 mcg/kg/hr. Once the participant reaches their maximum tolerated dose (as decided by the blinded treating physician), they will continue treatment for 48 ± 6 hours. This will be followed by a weaning phase that will similarly be at the discretion of the treating physician.
干预措施: Dexmedetomidine (Drug)
Placebo
Participants randomized to receive placebo will be started on normal saline. In similar fashion to the active comparator, participants will be titrated to their maximal tolerated dose, continue treatment for 48 ± 6 hours, and be weaned at the discretion of the blinded treating physician.
干预措施: Normal saline (Drug)
结局指标
主要结局
The primary outcome is a composite of the following: 1. All-cause in-hospital death AND/OR 2. Any in-hospital ventricular arrhythmia requiring treatment after study drug initiation.
时间窗: Duration of index hospitalization - an average of 2 weeks
Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo
次要结局
- Ventricular arrhythmia requiring treatment after study drug initiation(Duration of index hospitalization - an average of 2 weeks)
- Resuscitated cardiac arrest after study drug initiation(Duration of index hospitalization - an average of 2 weeks)
- Renal failure requiring new initiation of renal replacement therapy after study drug initiation(Duration of index hospitalization - an average of 2 weeks)
- Intubation following study drug initiation(Duration of index hospitalization - an average of 2 weeks)
- All-cause in-hospital death(Duration of index hospitalization - an average of 2 weeks)
- Ventricular Arrhythmia requiring treatment only during active study drug treatment(Duration of index hospitalization - an average of 2 weeks)
- Length of stay in the intensive care unit(Duration of index hospitalization - an average of 2 weeks)
- Length of stay in hospital(Duration of index hospitalization - an average of 2 weeks)
- Need for mechanical circulatory support device after study drug initiation(Duration of index hospitalization - an average of 2 weeks)
- Pacing or treatment with isoproterenol for treatment of bradyarrhythmia after study drug initiation.(Duration of index hospitalization - an average of 2 weeks)